ATE339968T1 - Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit - Google Patents
Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheitInfo
- Publication number
- ATE339968T1 ATE339968T1 AT02757930T AT02757930T ATE339968T1 AT E339968 T1 ATE339968 T1 AT E339968T1 AT 02757930 T AT02757930 T AT 02757930T AT 02757930 T AT02757930 T AT 02757930T AT E339968 T1 ATE339968 T1 AT E339968T1
- Authority
- AT
- Austria
- Prior art keywords
- autism
- syndrome
- treatment
- sensitive
- mental retardation
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 208000036626 Mental retardation Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28091501P | 2001-04-02 | 2001-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339968T1 true ATE339968T1 (de) | 2006-10-15 |
Family
ID=23075151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02757930T ATE339968T1 (de) | 2001-04-02 | 2002-04-02 | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6890931B2 (de) |
| EP (1) | EP1392363B1 (de) |
| JP (1) | JP2005500260A (de) |
| AT (1) | ATE339968T1 (de) |
| AU (1) | AU2002307049A1 (de) |
| CA (1) | CA2442478C (de) |
| DE (1) | DE60214846T2 (de) |
| ES (1) | ES2272754T3 (de) |
| WO (1) | WO2002078745A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6916821B2 (en) * | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| CA2532036A1 (en) * | 2003-07-11 | 2005-02-03 | Merck & Co., Inc. | Methods for identifying cell surface receptor protein modulators |
| SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
| US20080187492A1 (en) * | 2004-04-16 | 2008-08-07 | Mcbride Sean M J | Drosophila Models For Diseases Affecting Learning and Memory |
| CA2604454C (en) * | 2005-04-19 | 2014-06-03 | Otsuka Pharmaceutical Factory, Inc. | Artificial cerebrospinal fluid |
| WO2007002285A2 (en) * | 2005-06-21 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Methods for treating neurological and psychiatric conditions |
| WO2007029063A2 (en) * | 2005-07-29 | 2007-03-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Treatment and/or prevention of pervasive developmental disorders |
| WO2007035823A2 (en) * | 2005-09-20 | 2007-03-29 | Molecular Neuroimaging, Llc | Partial mglur5 antagonists and methods of use thereof |
| EP1948667B1 (de) | 2005-11-08 | 2012-04-11 | F. Hoffmann-La Roche AG | Thiazolo[4,5-c]pyridinderivative als antagonisten des mglu5-rezeptors |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| EP2125683B1 (de) * | 2006-12-19 | 2013-10-23 | The Board of Trustees of the University of Illinois | 3-benzofuranyl-4-indolyl-maleimide als potente gs-3 inhibitoren für neurodegenerative störungen |
| US8340770B2 (en) * | 2007-06-26 | 2012-12-25 | Durand Dominique M | Controlling seizure activity with electrical stimulation |
| WO2009047303A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder |
| US20090167322A1 (en) * | 2007-12-28 | 2009-07-02 | Erik Edmund Magnuson | Systems and method for classifying a substance |
| WO2010093859A1 (en) * | 2009-02-12 | 2010-08-19 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2011053636A1 (en) * | 2009-10-27 | 2011-05-05 | Mount Sinai School Of Medicine | Methods of treating psychiatric or neurological disorders with mglur antagonists |
| EP2544688B1 (de) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Verfahren und zusammensetzungen zur behandlung des angelman-syndroms |
| US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012024630A1 (en) * | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| US20130225623A1 (en) * | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| AR093077A1 (es) * | 2012-10-23 | 2015-05-20 | Hoffmann La Roche | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS |
| CN106102742A (zh) * | 2013-09-13 | 2016-11-09 | 因莱塔生物科技有限责任公司 | 利用细胞外钙调节针对代谢型谷氨酸受体的药物作用 |
| EP3303316B1 (de) | 2015-06-03 | 2020-01-29 | H. Hoffnabb-La Roche Ag | Ethynylderivate |
| US20240285637A1 (en) * | 2021-07-08 | 2024-08-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197820B1 (en) * | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| EP1002535A1 (de) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs |
| WO2001002342A1 (en) * | 1999-06-30 | 2001-01-11 | Igt Pharma Inc. | 2-aminoindane analogs |
| WO2001010846A2 (en) | 1999-08-05 | 2001-02-15 | Igt Pharma Inc. | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| SK2512002A3 (en) * | 1999-08-19 | 2002-07-02 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6313159B1 (en) * | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
-
2002
- 2002-04-02 JP JP2002577009A patent/JP2005500260A/ja active Pending
- 2002-04-02 CA CA002442478A patent/CA2442478C/en not_active Expired - Fee Related
- 2002-04-02 WO PCT/US2002/010211 patent/WO2002078745A2/en not_active Ceased
- 2002-04-02 ES ES02757930T patent/ES2272754T3/es not_active Expired - Lifetime
- 2002-04-02 AT AT02757930T patent/ATE339968T1/de not_active IP Right Cessation
- 2002-04-02 US US10/114,433 patent/US6890931B2/en not_active Expired - Lifetime
- 2002-04-02 DE DE60214846T patent/DE60214846T2/de not_active Expired - Lifetime
- 2002-04-02 EP EP02757930A patent/EP1392363B1/de not_active Expired - Lifetime
- 2002-04-02 AU AU2002307049A patent/AU2002307049A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002307049A1 (en) | 2002-10-15 |
| EP1392363B1 (de) | 2006-09-20 |
| EP1392363A2 (de) | 2004-03-03 |
| CA2442478A1 (en) | 2002-10-10 |
| ES2272754T3 (es) | 2007-05-01 |
| US20030100539A1 (en) | 2003-05-29 |
| DE60214846D1 (de) | 2006-11-02 |
| WO2002078745A3 (en) | 2002-11-28 |
| CA2442478C (en) | 2010-02-02 |
| DE60214846T2 (de) | 2007-05-16 |
| WO2002078745A2 (en) | 2002-10-10 |
| US6890931B2 (en) | 2005-05-10 |
| JP2005500260A (ja) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE339968T1 (de) | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| TR200101499T1 (tr) | Azepinoindol türevleri, hazırlanmaları ve kullanımları. | |
| MY140488A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| DE69725825D1 (de) | 5-HT1F-Agonisten | |
| ATE223399T1 (de) | Quinazolin-4-on ampa antagonisten | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| YU79103A (sh) | Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora | |
| GB0111186D0 (en) | Novel compounds | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| TR200000907T2 (tr) | Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri. | |
| DE50201565D1 (de) | 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE60225155D1 (de) | 3-substituierte 6,7-dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel | |
| ATE443060T1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
| ID25478A (id) | Agonis 5-ht1f | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE349210T1 (de) | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege | |
| BRPI0410026A (pt) | derivados de 3-amino-croman quinolina | |
| MXPA04001205A (es) | Compuesto para eliminar y/o mitigar la anhedonia. | |
| DE60100045D1 (de) | 1,2-Substituierte 2,3-dihydro-1H-5,9-dioxacyclohepta(f)inden-7-one und 7-substituierte Benzo(b)[1,4]dioxepin-3-one | |
| DK1055665T3 (da) | 3-(3-hydroxyphenyl)-3-aminopropionamidderivater | |
| ATE236625T1 (de) | Verwendung von 5ht2a und 5ht2a/c antagonisten zur herstellung von arzneimitteln zur behandlung des schnarchens und des herhoten widerstandes der oberen luftwege |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |